Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Inquiry Memorial
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Support and FAQs
    • NHS Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Hepatitis C Testing
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Subscribe to Search results

The AIDS Advisory document recorded that heat-treated commercial factor products were available. On the subject, Professor Bloom stated that during the early 1980s, several observers noted that there appeared to be a reduced risk of HIV infection and/or immunological abnormalities in patients with haemophilia B compared to those with haemophilia A.

Published on: 27 September, 2024

Following the fifth meeting by the AIDS Group, on 17 June 1985, more centres had transitioned to using commercial heat-treated Factor 9.

Published on: 27 September, 2024

Professor Bloom held, that around 1983-1984, that it was not necessary to inform patients or the parents of patients of the risks of AIDS.

Published on: 27 September, 2024

Professor Bloom held that he existence of the viruses causing serum hepatitis was well known to doctors caring for haemophiliacs during the 1960's, 1970's and later.

Published on: 27 September, 2024

The reference centre at the Manchester Royal Infirmary was part of a regional haemophilia service in North West England, which included Manchester Children's Hospital and the Lancaster Haemophilia Centre.

Published on: 27 September, 2024

Most patients being treated for haemophilia who were treated at the Manchester Royal Infirmary would have been informed that there was a high likelihood of them having AIDS. They were informed either by letter or through routine appointments.

Published on: 27 September, 2024

One of the aims of the appointment of Dr Wensley was to create a better understanding with the RTC and "a greater availability of cryoprecipitate and better treatment for all
haemophiliacs."

Published on: 27 September, 2024

Manchester Royal Infirmary's role was described in an article: "today with modern methods of treatment and patient assessment.. haemophiliacs are able to lead a near-normal, albeit hazardous, life. Their great salvation comes in small plastic bags containing as the cryoprecipitate."

Published on: 27 September, 2024

Dr Delamore preferred to administer cryoprecipitate but observed that if freeze-dried concentrate could be altered to be dissolved more easily and in smaller volume, "we would probably choose that preparation in preference to cryoprecipitate."

Published on: 27 September, 2024

The annual return for 1976 showed substantial use of cryoprecipitate, NHS concentrate and Kryobulin, with some use of Hemofil. Both FEIBA and porcine Factor 8 were also used in Manchester Haemophilia Centre.

Published on: 27 September, 2024

1977 saw an increase in the volume of NHS concentrate used at the Manchester Royal Infirmary, but a greater volume of commercial as well.

Published on: 27 September, 2024

In 1978, NHS concentrate was used in greatest measure at the Manchester Royal Infirmary, but significant quantities of commercial concentrates and cryoprecipitate were also used.

Published on: 27 September, 2024

In 1979, NHS concentrate was used in the greatest measure at the Manchester Royal Infirmary but with large quantities of commercial concentrates and cryoprecipitate all used as well.

Published on: 27 September, 2024

It was observed that usage of cryoprecipitate in the North West region remained high in comparison with the national position, due to the policies adopted by the regional haemophilia service.

Published on: 27 September, 2024

Dr Wensley recorded that the NHS concentrate compared well with commercial. and that he was gradually changing his home treatment patients from commercial to NHS concentrate, with the plan that commercial concentrate would then be used only in operations.

Published on: 27 September, 2024

Dr Wensley reported that certain batches of Factor VIII concentrate had failed to comply with the new B.P. limit.

Published on: 27 September, 2024

Dr Gunson stated that Dr Wensley "worked very hard and devised a semi-automated method for producing high quality cryoprecipitate from which the patients in the region derived considerable benefit."

Published on: 27 September, 2024

Dr Delamore identified the incidence of hepatitis in haemophilia as being the highest priority in a March 1977 letter to Dr Rizza.

Published on: 27 September, 2024

An AIDS information leaflet was determined to be in the best interests of public health, despite potential sensitivity relating to homosexuals. Ministers were asked to agree to the funding and publication.

Published on: 24 September, 2024

Information was provided regarding the introduction of an information leaflet on AIDS by the BTS. This information encouraged the self exclusion of high risk donors.

Published on: 24 September, 2024

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2107
  • Page 2108
  • Page 2109
  • Page 2110
  • Current page 2111
  • Page 2112
  • Page 2113
  • Page 2114
  • Page 2115
  • …
  • Next page Next
  • Last page Last

Inquiry

  • Home
  • About
  • Approach
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.